Redx Pharma is a drug discovery and development company formed in 2010. It is focused on improving the characteristics of existing drug classes to create best-in-class new drugs in the areas of cancer, infection and autoimmune disease. The company's work has been endorsed by partnerships with global pharmaceutical companies and the NHS.
World Cancer Day 2016
3 February 2016
Redx Pharma Plc is supporting World Cancer Day, a global event that serves as a focal point in the fight against cancer, which currently claims the lives of 8.2 million people each year.
The event, which takes place on February 4, highlights the vast effort devoted to fighting the disease and the importance of a healthy lifestyle.
Dr Matilda Bingham, executive director of Redx Oncology, said:
World Cancer Day is a welcome opportunity to highlight issues that affect us all. As one of the drug development companies creating a new generation of therapies aimed at the very heart of cancer — the genetic changes that make cells malignant in the first place — we do think real progress is being made in the battle against this disease.
We are now in a new era of cancer treatment, where the focus is on using the patient's own immune system to seek out and destroy tumour cells wherever they appear. Cancer immunotherapy is now the cutting edge of cancer research and is predicted to be a game-changer in the fight to turn cancer from a disease that prematurely ends lives into an illness that can be managed.
As a fast-growing dynamic business we are continually looking for talented people to join our team.
21 January 2016
Announcing our annual report and accounts for the year ended 30 September 2015 is now available for download.
Please also note our AGM is scheduled for 9am on 24 February at the offices of Brown Shipley, 3 Hardman Street, Manchester M3 3HF.
Discovering and developing new therapeutics in the area of infectious disease generating a pipeline of novel antibacterial & antiviral drugs.
Modulating the immune system with novel small molecules to treat a range of diseases with high unmet medical need.
Applying our proprietary method to deliver multiple development candidates across a range of mechanistic approaches in cancer treatment.